|

Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

RECRUITINGN/ASponsored by Rambam Health Care Campus
Actively Recruiting
PhaseN/A
SponsorRambam Health Care Campus
Started2025-11-01
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07384013

Summary

Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult oncology patients (≥18 years old).
* Receiving apixaban or rivaroxaban for anticoagulation.
* New/current metamizole users taking at least 1g TID for pain management.
* Platelets ≥100×10⁹/L
* ECOG PS\<3
* Provided informed consent

Exclusion Criteria:

* History of allergic reaction to metamizole or DOACs.
* Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT/zonda)

Conditions4

CancerCoagulation DefectOncologic DiseasesPain Management

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.